CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice

Satoshi Takanashi; Yuko Kaneko; Tsutomu Takeuchi

doi:10.1136/annrheumdis-2019-216607

CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice

Satoshi Takanashi
, Yuko Kaneko
, Tsutomu Takeuchi

研究成果: Letter › 査読

本文言語	English
ページ（範囲）	671-674
ページ数	4
ジャーナル	Annals of the rheumatic diseases
巻	79
号	5
DOI	https://doi.org/10.1136/annrheumdis-2019-216607
出版ステータス	Published - 2020 5月 1

ASJC Scopus subject areas

生化学、遺伝学、分子生物学一般
リウマチ学
免疫アレルギー学
免疫学

文献へのアクセス

10.1136/annrheumdis-2019-216607

他のファイルとリンク

引用スタイル

@article{934af230825d466681e10c2a21177cf6,

title = "CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice",

keywords = "DAS28, disease activity, rheumatoid arthritis",

author = "Satoshi Takanashi and Yuko Kaneko and Tsutomu Takeuchi",

note = "Funding Information: Competing interests YK has received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT has received research grants or speaking fees from Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Teijin Pharma, AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Abbivie GK, Nipponkayaku, Janssen, Pharmaceutical K.K., Taiho Pharmaceutical and Pfizer Japan.",

year = "2020",

month = may,

day = "1",

doi = "10.1136/annrheumdis-2019-216607",

language = "English",

volume = "79",

pages = "671--674",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice

AU - Takanashi, Satoshi

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

N1 - Funding Information: Competing interests YK has received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT has received research grants or speaking fees from Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Teijin Pharma, AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Abbivie GK, Nipponkayaku, Janssen, Pharmaceutical K.K., Taiho Pharmaceutical and Pfizer Japan.

PY - 2020/5/1

Y1 - 2020/5/1

KW - DAS28

KW - disease activity

KW - rheumatoid arthritis

UR - https://www.scopus.com/pages/publications/85078945480

UR - https://www.scopus.com/pages/publications/85078945480#tab=citedBy

U2 - 10.1136/annrheumdis-2019-216607

DO - 10.1136/annrheumdis-2019-216607

M3 - Letter

C2 - 31996365

AN - SCOPUS:85078945480

SN - 0003-4967

VL - 79

SP - 671

EP - 674

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 5

ER -